Page 1552 - Hematology_ Basic Principles and Practice ( PDFDrive )

Chapter 85 T-Cell Lymphomas 1379

stable disease. Currently, a phase II study is enrolling relapsed/ Kaye FJ, Bunn PA, Jr, Steinberg SM, et al: A randomized trial comparing
refractory MF/SS patients to receive the anti–PD-1 antibody pem- combination electron-beam radiation and chemotherapy with topical
bolizumab (ClinicalTrials.gov identifier NCT02243579). therapy in the initial treatment of mycosis fungoides. N Engl J Med
321:1784, 1989.
Mercadal S, Briones J, Xicoy B, et al: Intensive chemotherapy (high-dose
FUTURE DIRECTIONS CHOP/ESHAP regimen) followed by autologous stem-cell transplanta-
tion in previously untreated patients with peripheral T-cell lymphoma.
Knowledge of the unique cytokine milieu associated with these Ann Oncol 19:958, 2008.
neoplastic T cells has led to trials testing cytokines that may inhibit O’Connor OA, Heaney ML, Schwartz L, et al: Clinical experience with intra-
the growth of these cells, such as IL-12 or IL-2. Vaccine approaches venous and oral formulations of the novel histone deacetylase inhibitor
may be practical. suberoylanilide hydroxamic acid in patients with advanced hematologic
Significant amounts of basic and practical research have been malignancies. J Clin Oncol 24:166, 2006.
performed in an attempt to control this disease, and future treatment O’Connor OA, Horwitz S, Hamlin P, et al: Phase II-I-II study of two differ-
approaches will likely depend on further understanding of the ent doses and schedules of pralatrexate, a high-affinity substrate for the
molecular and genetic bases of these disorders. We hope that one of reduced folate carrier, in patients with relapsed or refractory lymphoma
the strategies under development or study will lead to treatments that reveals marked activity in T-cell malignancies. J Clin Oncol 27:4357,
can control the disease and symptomatic effects, or even cure this 2009.
neoplasm in the majority of afflicted patients. O’Connor OA, Pro B, Pinter-Brown L, et al: Pralatrexate in patients with
relapsed or refractory peripheral T-cell lymphoma: results from the pivotal
PROPEL study. J Clin Oncol 29:1182, 2011.
SUGGESTED READINGS Odejide O, et al: A targeted mutational landscape of angioimmunoblastic
T-cell lymphoma. Blood 123(9):1293–1296, 2014.
Boddicker RL, et al: The oncogenic transcription factor IRF4 is regulated Olsen E, Kim YH, Kuzel T, et al: Vorinostat (suberoylanilide hydroxamic
by a novel CD30/NF-kappaB positive feedback loop in peripheral T-cell acid, SAHA) is clinically active in advanced cutaneous T-cell lymphoma
lymphoma. Blood 2015. (CTCL): Results of a phase IIb trial. ASCO annual meeting proceedings
Bunn PA, Jr, Schechter GP, Jaffe E, et al: Clinical course of retrovirus- part I. J Clin Oncol 24:7500, 2006.
associated adult T-cell lymphoma in the United States. N Engl J Med Parrilla Castellar ER, et al: ALK-negative anaplastic large cell lymphoma is a
309:257, 1983. genetically heterogeneous disease with widely disparate clinical outcomes.
Cairns RA, Iqbal J, Lemonnier F, et al: IDH2 mutations are frequent in Blood 124(9):1473–1480, 2014.
angioimmunoblastic T-cell lymphoma. Blood 119:1901, 2012. Pechloff K, Holch J, Ferch U, et al: The fusion kinase ITK-SYK mimics a T
Coiffier B, Pro B, Prince HM, et al: Results from a pivotal, open-label, cell receptor signal and drives oncogenesis in conditional mouse models
phase II study of romidepsin in relapsed or refractory peripheral T-cell of peripheral T cell lymphoma. J Exp Med 207:1031, 2010.
lymphoma after prior systemic therapy. J Clin Oncol 30:631, 2012. Piekarz RL, Frye R, Turner M, et al: Phase II multi-institutional trial of the
Corradini P, Tarella C, Zallio F, et al: Long-term follow-up of patients with histone deacetylase inhibitor romidepsin as monotherapy for patients with
peripheral T-cell lymphomas treated up-front with high-dose chemo- cutaneous T-cell lymphoma. J Clin Oncol 27:5410, 2009.
therapy followed by autologous stem cell transplantation. Leukemia Prince HM, Duvic M, Martin A, et al: Phase III placebo-controlled trial of
20:1533, 2006. denileukin diftitox for patients with cutaneous T-cell lymphoma. J Clin
Couronne L, Bastard C, Bernard OA: TET2 and DNMT3A mutations in Oncol 28:1870, 2010.
human T-cell lymphoma. N Engl J Med 366:95, 2012. Quivoron C, Couronné L, Della Valle V, et al: TET2 inactivation results in
Cuadros M, Dave SS, Jaffe ES, et al: Identification of a proliferation signature pleiotropic hematopoietic abnormalities in mouse and is a recurrent event
related to survival in nodal peripheral T-cell lymphomas. J Clin Oncol during human lymphomagenesis. Cancer Cell 20:25, 2011.
25:3321, 2007. Reimer P, Rüdiger T, Geissinger E, et al: Autologous stem-cell transplantation
Feldman AL, Sun DX, Law ME, et al: Overexpression of Syk tyrosine kinase as first-line therapy in peripheral T-cell lymphomas: results of a prospec-
in peripheral T-cell lymphomas. Leukemia 22:1139, 2008. tive multicenter study. J Clin Oncol 27:106, 2009.
Gallamini A, Stelitano C, Calvi R, et al: Peripheral T-cell lymphoma unspeci- Scarisbrick JJ: New drugs in cutaneous T-cell lymphomas. Curr Opin Oncol
fied (PTCL-U): a new prognostic model from a retrospective multicentric 28(5):384–389, 2016.
clinical study. Blood 103:2474, 2004. Schmitz N, Trümper L, Ziepert M, et al: Treatment and prognosis of
Ghez D, Danu A, Ribrag V: Investigational drugs for T-cell lymphoma. mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell
Expert Opin Investig Drugs 25(2):171–181, 2016. lymphoma treated in studies of the German High-Grade Non-Hodgkin
Hayat MJ, Howlader N, Reichman ME, et al: Cancer statistics, trends, and Lymphoma Study Group. Blood 116:3418, 2010.
multiple primary cancer analyses from the Surveillance, Epidemiology, Sharma M, Pro B: Bone Marrow Transplantation for Peripheral T-Cell
and End Results (SEER) Program. Oncologist 12:20, 2007. Non-Hodgkins’ Lymphoma in First Remission. Curr Treat Options Oncol
Horwitz SM, Kim YH, Foss F, et al: Identification of an active, well-tolerated 16(7):34, 2015.
dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell Siegel RS, Pandolfino T, Guitart J, et al: Primary cutaneous T-cell lymphoma:
lymphoma. Blood 119:4115, 2012. review and current concepts. J Clin Oncol 18:2908, 2000.
Iqbal J, et al: Gene expression signatures delineate biological and prognostic Vose J, Armitage J, Weisenburger D: International peripheral T-cell and
subgroups in peripheral T-cell lymphoma. Blood 123(19):2915–2923, natural killer/T-cell lymphoma study: pathology findings and clinical
2014. outcomes. J Clin Oncol 26:4124, 2008.
Iqbal J, Weisenburger DD, Greiner TC, et al: Molecular signatures to Wang T, et al: GATA-3 expression identifies a high-risk subset of PTCL, NOS
improve diagnosis in peripheral T-cell lymphoma and prognostication in with distinct molecular and clinical features. Blood 123(19):3007–3015,
angioimmunoblastic T-cell lymphoma. Blood 115:1026, 2010. 2014.
Iqbal J, Wright G, Wang C, et al: Gene expression signatures delineate Weisenburger DD, et al: Peripheral T-cell lymphoma, not otherwise specified:
biological and prognostic subgroups in peripheral T-cell lymphoma. Blood a report of 340 cases from the International Peripheral T-cell Lymphoma
123(19):2915–2923, 2014. Project. Blood 117(12):3402–3408, 2011.
Ishida T, et al: Dose intensified chemotherapy alone or in combination with Whittaker S, Hoppe R, Prince HM: How I treat mycosis fungoides and
mogamulizumab in newly diagnosed aggressive adult T-cell leukemia- Sézary syndrome. Blood 127(25):3142–3153, 2016.
lymphoma: Randomized Phase II study. Br J Hematology 169(5):672–682, Willemze R, Beljaards RC: Spectrum of primary cutaneous CD30 (Ki-1)-
2015. positive lymphoproliferative disorders. A proposal for classification and
Kataoka K, et al: Integrated molecular analysis of adult T cell leukemia/ guidelines for management and treatment. J Am Acad Dermatol 28:973,
lymphoma. Nat Genet 47(11):1304–1315, 2015. 1993.